Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials group study 359

Courtney V. Fletcher, Hongyu Jiang, Richard C. Brundage, Edward P. Acosta, Richard Haubrich, David Katzenstein, Roy M. Gulick

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

AIDS Clinical Trials Group study 359 was a controlled study of saquinavir with either ritonavir or nelfinavir, together with delavirdine, adefovir, or both, in indinavir-experienced persons. Saquinavir was common in all study arms, and the study investigated relationships among characteristics of patients, saquinavir area under the curve (AUC) and trough concentrations (C min), and virologic response. Concentrations of saquinavir were higher when it was combined with ritonavir than when it was combined with nelfinavir and were lower with adefovir-containing regimens. Females had higher AUC and Cmin values than did males. Higher saquinavir AUC and C min values were associated with a greater likelihood of human immunodeficiency virus (HIV) RNA levels ≤500 copies/mL (P = .008) and were better predictors of response than was the saquinavir inhibitory quotient Males had a lower probability of having HIV RNA levels ≤500 copies/mL at week 16 than did females (28% vs. 42%; adjusted odds ratio, 0.43). In this study, a greater proportion of females had HIV RNA levels ≤500 copies/mL than did males, which can be attributed to higher concentrations of saquinavir in females than in males.

Original languageEnglish (US)
Pages (from-to)1176-1184
Number of pages9
JournalJournal of Infectious Diseases
Volume189
Issue number7
DOIs
StatePublished - Apr 1 2004

Fingerprint

Saquinavir
Sex Characteristics
Acquired Immunodeficiency Syndrome
Clinical Trials
Pharmacology
Nelfinavir
Area Under Curve
Ritonavir
HIV
RNA
Delavirdine
Indinavir
Odds Ratio

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials group study 359. / Fletcher, Courtney V.; Jiang, Hongyu; Brundage, Richard C.; Acosta, Edward P.; Haubrich, Richard; Katzenstein, David; Gulick, Roy M.

In: Journal of Infectious Diseases, Vol. 189, No. 7, 01.04.2004, p. 1176-1184.

Research output: Contribution to journalArticle

Fletcher, CV, Jiang, H, Brundage, RC, Acosta, EP, Haubrich, R, Katzenstein, D & Gulick, RM 2004, 'Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials group study 359', Journal of Infectious Diseases, vol. 189, no. 7, pp. 1176-1184. https://doi.org/10.1086/382754
Fletcher, Courtney V. ; Jiang, Hongyu ; Brundage, Richard C. ; Acosta, Edward P. ; Haubrich, Richard ; Katzenstein, David ; Gulick, Roy M. / Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials group study 359. In: Journal of Infectious Diseases. 2004 ; Vol. 189, No. 7. pp. 1176-1184.
@article{a395facf2553447abe0a02595ab6ed25,
title = "Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials group study 359",
abstract = "AIDS Clinical Trials Group study 359 was a controlled study of saquinavir with either ritonavir or nelfinavir, together with delavirdine, adefovir, or both, in indinavir-experienced persons. Saquinavir was common in all study arms, and the study investigated relationships among characteristics of patients, saquinavir area under the curve (AUC) and trough concentrations (C min), and virologic response. Concentrations of saquinavir were higher when it was combined with ritonavir than when it was combined with nelfinavir and were lower with adefovir-containing regimens. Females had higher AUC and Cmin values than did males. Higher saquinavir AUC and C min values were associated with a greater likelihood of human immunodeficiency virus (HIV) RNA levels ≤500 copies/mL (P = .008) and were better predictors of response than was the saquinavir inhibitory quotient Males had a lower probability of having HIV RNA levels ≤500 copies/mL at week 16 than did females (28{\%} vs. 42{\%}; adjusted odds ratio, 0.43). In this study, a greater proportion of females had HIV RNA levels ≤500 copies/mL than did males, which can be attributed to higher concentrations of saquinavir in females than in males.",
author = "Fletcher, {Courtney V.} and Hongyu Jiang and Brundage, {Richard C.} and Acosta, {Edward P.} and Richard Haubrich and David Katzenstein and Gulick, {Roy M.}",
year = "2004",
month = "4",
day = "1",
doi = "10.1086/382754",
language = "English (US)",
volume = "189",
pages = "1176--1184",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials group study 359

AU - Fletcher, Courtney V.

AU - Jiang, Hongyu

AU - Brundage, Richard C.

AU - Acosta, Edward P.

AU - Haubrich, Richard

AU - Katzenstein, David

AU - Gulick, Roy M.

PY - 2004/4/1

Y1 - 2004/4/1

N2 - AIDS Clinical Trials Group study 359 was a controlled study of saquinavir with either ritonavir or nelfinavir, together with delavirdine, adefovir, or both, in indinavir-experienced persons. Saquinavir was common in all study arms, and the study investigated relationships among characteristics of patients, saquinavir area under the curve (AUC) and trough concentrations (C min), and virologic response. Concentrations of saquinavir were higher when it was combined with ritonavir than when it was combined with nelfinavir and were lower with adefovir-containing regimens. Females had higher AUC and Cmin values than did males. Higher saquinavir AUC and C min values were associated with a greater likelihood of human immunodeficiency virus (HIV) RNA levels ≤500 copies/mL (P = .008) and were better predictors of response than was the saquinavir inhibitory quotient Males had a lower probability of having HIV RNA levels ≤500 copies/mL at week 16 than did females (28% vs. 42%; adjusted odds ratio, 0.43). In this study, a greater proportion of females had HIV RNA levels ≤500 copies/mL than did males, which can be attributed to higher concentrations of saquinavir in females than in males.

AB - AIDS Clinical Trials Group study 359 was a controlled study of saquinavir with either ritonavir or nelfinavir, together with delavirdine, adefovir, or both, in indinavir-experienced persons. Saquinavir was common in all study arms, and the study investigated relationships among characteristics of patients, saquinavir area under the curve (AUC) and trough concentrations (C min), and virologic response. Concentrations of saquinavir were higher when it was combined with ritonavir than when it was combined with nelfinavir and were lower with adefovir-containing regimens. Females had higher AUC and Cmin values than did males. Higher saquinavir AUC and C min values were associated with a greater likelihood of human immunodeficiency virus (HIV) RNA levels ≤500 copies/mL (P = .008) and were better predictors of response than was the saquinavir inhibitory quotient Males had a lower probability of having HIV RNA levels ≤500 copies/mL at week 16 than did females (28% vs. 42%; adjusted odds ratio, 0.43). In this study, a greater proportion of females had HIV RNA levels ≤500 copies/mL than did males, which can be attributed to higher concentrations of saquinavir in females than in males.

UR - http://www.scopus.com/inward/record.url?scp=1842450852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842450852&partnerID=8YFLogxK

U2 - 10.1086/382754

DO - 10.1086/382754

M3 - Article

C2 - 15031785

AN - SCOPUS:1842450852

VL - 189

SP - 1176

EP - 1184

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 7

ER -